Zura Bio (NASDAQ:ZURA) Coverage Initiated by Analysts at Piper Sandler

Piper Sandler started coverage on shares of Zura Bio (NASDAQ:ZURA) in a research note published on Friday morning, MarketBeat reports. The brokerage issued an overweight rating and a $26.00 price objective on the stock.

Separately, Oppenheimer reissued an outperform rating and set a $16.00 target price (down previously from $17.00) on shares of Zura Bio in a research report on Monday, April 1st. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Buy and an average price target of $18.00.

Zura Bio Price Performance

NASDAQ:ZURA opened at $4.69 on Friday. The business’s fifty day moving average price is $3.28 and its 200 day moving average price is $3.92. Zura Bio has a 12 month low of $2.00 and a 12 month high of $14.00.

Insider Activity

In other news, Director Amit Munshi acquired 159,744 shares of Zura Bio stock in a transaction on Monday, April 22nd. The stock was bought at an average price of $3.13 per share, for a total transaction of $499,998.72. Following the completion of the purchase, the director now owns 777,384 shares in the company, valued at $2,433,211.92. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders bought 170,926 shares of company stock valued at $534,998. Insiders own 15.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Lynx1 Capital Management LP purchased a new stake in shares of Zura Bio in the third quarter valued at about $65,000. Forefront Analytics LLC purchased a new stake in Zura Bio during the 3rd quarter valued at approximately $95,000. Bank of New York Mellon Corp acquired a new stake in Zura Bio during the 3rd quarter worth approximately $224,000. Raymond James & Associates lifted its position in Zura Bio by 14.0% during the 3rd quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock worth $511,000 after acquiring an additional 9,481 shares during the period. Finally, Eisler Capital US LLC purchased a new position in shares of Zura Bio in the 3rd quarter valued at approximately $660,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.